MARCELO ARAUJO QUEIROZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Genitourinary imaging(2022) BARBOSA, F. de Galiza; GALGANO, S. J.; BOTWIN, A. L.; GONGORA, A. B. Lara; SAWAYA, G.; BARONI, R. H.; QUEIROZ, M. A.The successful evaluation of genitourinary malignancies with positron emission tomography/magnetic resonance imaging (PET/MRI) requires strict adherence to specialized protocols and workflows. PET/MRI can be used for several uro-oncologic applications and offers several advantages as compared to conventional imaging modalities. Fluorodeoxyglucose still remains the most utilized radiopharmaceutical for the evaluation of genitourinary malignancies but prostate-specific membrane antigen has emerged as a frontrunner in the evaluation of prostate cancer. Recognition of the strengths and limitations of PET/MRI for evaluating tumors of the urinary tract is essential for improving its diagnostic accuracy. © 2023 Elsevier Inc. All rights reserved.
- Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease(2022) QUEIROZ, Marcelo A.; ORTEGA, Cinthia D.; FERREIRA, Felipe R.; CAPARELI, Fernanda C.; NAHAS, Sergio C.; CERRI, Giovanni G.; BUCHPIGUEL, Carlos A.Purpose: To analyze the associations between positron emission tomography (PET)/magnetic resonance imaging (MRI) features for primary rectal tumors and metastases. Procedures: Between November 2016 and April 2018, 101 patients with rectal adenocarcinoma were included in this prospective study (NCT02537340) for whole-body PET/MRI for baseline staging. Two readers analyzed the PET/MRI; they assessed the semiquantitative PET features of the primary tumor and the N- and M-stages. Another reader analyzed the MRI features for locoregional staging. The reference standard for confirming metastatic disease was biopsy or imaging follow-up. Nonparametric tests were used to compare the PET/MRI features of the participants with or without metastatic disease. Binary logistic regression was used to evaluate the associations between the primary tumor PET/MRI features and metastatic disease. Results: A total of 101 consecutive participants (median age 62 years; range: 33-87 years) were included. Metastases were detected in 35.6% (36 of 101) of the participants. Among the PET/MRI features, higher tumor lesion glycolysis (352.95 vs 242.70; P =.46) and metabolic tumor volume (36.15 vs 26.20; P =.03) were more frequent in patients with than in those without metastases. Additionally, patients with metastases had a higher incidence of PET-positive (64% vs 32%; P =.009) and MRIpositive (56% vs 32%; P =.03) mesorectal lymph nodes, extramural vascular invasion (86% vs 49%; P >.001), and involvement of mesorectal fascia (64% vs 42%; P =.04); there were also differences between the mrT stages of these two groups (P =.008). No differences in the maximum standardized uptake values for the primary tumors in patients with and without metastases were observed (18.9 vs 19.1; P =.56). Multivariable logistic regression showed that extramural vascular invasion on MRI was the only significant predictor (adjusted odds ratio, 3.8 [95% CI: 1.1, 13.9]; P =.001). Conclusion: PET/MRI facilitated the identification of participants with a high risk of metastatic disease, though these findings were based mainly on MRI features.
- Radiopharmaceuticals and contrast agents(2022) KAKO, B.; ROMERO, A. B.; QUEIROZ, M. A.; GALGANO, S. J.; CARAVAN, P.; ESFAHANI, S. A.PET/MRI is the most advanced imaging technology available for clinical use. Its enormous potential can be unleashed only when both PET and MRI are properly and complementarily used. This starts with the choice of the most appropriate PET radiopharmaceutical and MR contrast agent for each specific clinical scenario and continues with building the most tailored PET/MRI protocol that fits the specific properties of the chosen radiopharmaceutical along with the potential additional information provided by the MRI contrast agent. This chapter provides a clinical and practical perspective of the most relevant and commonly used radiopharmaceuticals and MR contrast agents. © 2023 Elsevier Inc. All rights reserved.
- Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease (vol 24, pg 453, 2021)(2022) QUEIROZ, Marcelo A.; ORTEGA, Cinthia D.; FERREIRA, Felipe R.; CAPARELI, Fernanda C.; NAHAS, Sergio C.; CERRI, Giovanni G.; BUCHPIGUEL, Carlos A.